In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away
August 05 2021 - 7:30AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow
announced today that its Chairman of the Board, Tadataka (Tachi)
Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021.
“As I reflect on my time with Tachi, one word in the forefront
of my mind is impact. His passion for identifying and solving big
problems in healthcare and biotech, as well as his penchant for
impacting humanity, is evident in his legacy of professional and
academic achievements. There are few others whose work has touched
so many lives,” said Mark McKenna, President and CEO of Prometheus
Biosciences. “On behalf of the Board of Directors, Prometheus
management team and employees, we deeply mourn his loss and extend
our sympathies to his family."
Over the course of his career, Dr. Yamada left an impact on many
lives as a physician scientist who became a pillar of the
healthcare community and a luminary leader and mentor for many
companies. He had served as Prometheus’ Board Chair since June 2018
and as a Venture Partner at Frazier Life Sciences since June 2015.
He was a co-founder of and served as Chair of the Board of
Directors for Phathom Pharmaceuticals, Passage Bio and Scout Bio.
He also served as Chair of Icosavax and served as member of the
Board of Directors of Agilent Technologies, Inc., Takeda
Pharmaceutical Company Ltd, GlaxoSmithKline Inc., and CSL
Limited.
Before joining Frazier, Dr. Yamada was Chief Medical and
Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as a
member of the Board of Directors, where he was responsible for all
of Takeda’s research & development activities. Prior to Takeda,
Dr. Yamada was President of the Bill & Melinda Gates Foundation
Global Health Program in Seattle, where he oversaw over $9 billion
in grants for applying technologies to address major health
challenges of the developing world.
About Prometheus BiosciencesPrometheus
Biosciences, Inc. is a clinical-stage biotechnology company
pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of immune-mediated
diseases, starting first with inflammatory bowel disease (IBD). The
Company’s precision medicine platform, Prometheus360, combines
proprietary bioinformatics discovery methods with one of the
world’s largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets. Prometheus is headquartered in
San Diego, CA.
Prometheus Biosciences Contact:Noel KurdiVP
Investor Relations and Communications(646)
241-4400nkurdi@prometheusbiosciences.com
Media Contact:Jake RobisonCanaleComm, an
Ashfield Health Company(619)
849-5383jake.robison@canalecomm.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2024 to May 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From May 2023 to May 2024